Can you trust companies that say their plastic products are recyclable? US regulators may crack down on deceptive claims
Hundreds sue over alleged sexual abuse in Illinois youth detention centers
Jury reaches verdict in Colorado grocery store massacre trial
Thousands flee southern Lebanon in search of safety and shelter
Feds bust Connecticut dealers accused of selling counterfeit pills throughout the US
Canadian detained by China says he experienced psychological torture
Trump Media shares tumble to new lows after insider selling curbs expire
Mexico's inflation expected to slow in first half of September: Reuters poll
Boeing makes a 'best and final offer' to striking union workers
Memphis, Tulane and South Florida have decided to remain in the AAC after overtures from new Pac-12
Trump will attend Al Smith charity dinner that Harris is skipping to campaign in battleground state
LSU linebacker Harold Perkins Jr.'s season is ended by a knee injury, coach confirms
Uncategorized
China drugmakers axe IPO plans as they face scrutiny in anti-graft drive
– A growing number of healthcare companies in China are shelving their initial public offering (IPO) plans as its stock exchanges have stepped up scrutiny of the pharmaceutical industry’s business practices amid an escalating anti-corruption drive. Healthcare stocks have already slumped in China since the government in late July launched a year-long anti-graft campaign, targeting what it said was the rampant practice of bribing of doctors in drug and medical equipment sales. Pharmaceuticals is the latest industry in the cross-hairs of Chinese regulators, and the tighter vetting of the sector’s IPO
August 11, 2023